{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:24:52Z","timestamp":1790637892172,"version":"4.1.0"},"reference-count":91,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1655212"],"award-info":[{"award-number":["1655212"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI134195"],"award-info":[{"award-number":["R01AI134195"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007247","name":"Miller Institute for Basic Research in Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Triple-drug therapies have transformed HIV from a fatal condition to a chronic one. These therapies should prevent HIV drug resistance evolution, because one or more drugs suppress any partially resistant viruses. In practice, such therapies drastically reduced, but did not eliminate, resistance evolution. In this article, we reanalyze published data from an evolutionary perspective and demonstrate several intriguing patterns about HIV resistance evolution - resistance evolves (1) even after years on successful therapy, (2) sequentially, often via one mutation at a time and (3) in a partially predictable order. We describe how these observations might emerge under two models of HIV drugs varying in space or time. Despite decades of work in this area, much opportunity remains to create models with realistic parameters for three drugs, and to match model outcomes to resistance rates and genetic patterns from individuals on triple-drug therapy. Further, lessons from HIV may inform other systems.<\/jats:p>","DOI":"10.7554\/elife.69032","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T11:01:01Z","timestamp":1630580461000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.69032","source":"Crossref","is-referenced-by-count":57,"title":["Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity"],"prefix":"10.7554","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2915-089X","authenticated-orcid":true,"given":"Alison F","family":"Feder","sequence":"first","affiliation":[{"name":"Department of Integrative Biology, University of California, Berkeley, Berkeley, United States"},{"name":"Department of Genome Sciences, University of Washington, Seattle, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin N","family":"Harper","sequence":"additional","affiliation":[{"name":"Harper Health and Science Communications, LLC, Seattle, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanson J","family":"Brumme","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-6578","authenticated-orcid":true,"given":"Pleuni S","family":"Pennings","sequence":"additional","affiliation":[{"name":"Department of Biology, San Francisco State University, San Francisco, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"9864","DOI":"10.1128\/JVI.00915-10","article-title":"Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication","volume":"84","author":"Abram","year":"2010","journal-title":"Journal of Virology"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1093\/jac\/dkv183","article-title":"Efavirenz and the CNS: what we already know and questions that need to be answered","volume":"70","author":"Apostolova","year":"2015","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00042560-199901010-00006","article-title":"Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex","volume":"20","author":"Aweeka","year":"1999","journal-title":"Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/jac\/dkh162","article-title":"Paradoxes of adherence and drug resistance to HIV antiretroviral therapy","volume":"53","author":"Bangsberg","year":"2004","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/01.aids.0000199825.34241.49","article-title":"Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness","volume":"20","author":"Bangsberg","year":"2006","journal-title":"AIDS"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11904-007-0010-0","article-title":"Adherence-resistance relationships to combination HIV antiretroviral therapy","volume":"4","author":"Bangsberg","year":"2007","journal-title":"Current HIV\/AIDS Reports"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1021\/mp200458e","article-title":"Exploiting evolution to treat drug resistance: combination therapy and the double bind","volume":"9","author":"Basanta","year":"2012","journal-title":"Molecular Pharmaceutics"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1126\/science.aag0822","article-title":"Spatiotemporal microbial evolution on antibiotic landscapes","volume":"353","author":"Baym","year":"2016","journal-title":"Science"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/11318110-000000000-00000","article-title":"Intracellular pharmacokinetics of antiretroviral drugs in HIV-Infected patients, and their correlation with drug action","volume":"49","author":"Bazzoli","year":"2010","journal-title":"Clinical Pharmacokinetics"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1086\/430005","article-title":"Estimating HIV evolutionary pathways and the genetic barrier to drug resistance","volume":"191","author":"Beerenwinkel","year":"2005","journal-title":"The Journal of Infectious Diseases"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1089\/cmb.2005.12.584","article-title":"Learning multiple evolutionary pathways from cross-sectional data","volume":"12","author":"Beerenwinkel","year":"2005","journal-title":"Journal of Computational Biology"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1752-0509-7-11","article-title":"A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns","volume":"7","author":"Bershteyn","year":"2013","journal-title":"BMC Systems Biology"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nm.3841","article-title":"Studying clonal dynamics in response to Cancer therapy using high-complexity barcoding","volume":"21","author":"Bhang","year":"2015","journal-title":"Nature Medicine"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/infdis\/165.1.105","article-title":"Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects","volume":"165","author":"Boucher","year":"1992","journal-title":"Journal of Infectious Diseases"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/jac\/dkl386","article-title":"Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation","volume":"58","author":"Braithwaite","year":"2006","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/infdis\/167.1.21","article-title":"2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial","volume":"167","author":"Browne","year":"1993","journal-title":"Journal of Infectious Diseases"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1098\/rsif.2012.0127","article-title":"Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV","volume":"9","author":"Cadosch","year":"2012","journal-title":"Journal of the Royal Society Interface"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/01.aids.0000171409.38490.48","article-title":"Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV","volume":"19","author":"Capparelli","year":"2005","journal-title":"AIDS"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S0277-9536(99)00468-2","article-title":"Adherence to HIV combination therapy","volume":"50","author":"Chesney","year":"2000","journal-title":"Social Science & Medicine"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0022-5193(76)90169-7","article-title":"Derivation and properties of Michaelis-Menten type and hill type equations for reference ligands","volume":"59","author":"Chou","year":"1976","journal-title":"Journal of Theoretical Biology"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40262-015-0257-3","article-title":"Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations","volume":"54","author":"Decloedt","year":"2015","journal-title":"Clinical Pharmacokinetics"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1310\/hct.2000.1.1.008","article-title":"Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the panel on clinical practices for treatment of HIV infection","volume":"1","author":"Department of Health and Human Services. Panel on Clinical Practices for Treatment of HIV Infection.","year":"2000","journal-title":"HIV Clinical Trials"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/jac\/dkg269","article-title":"The mutant selection window and antimicrobial resistance","volume":"52","author":"Drlica","year":"2003","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/QAI.0b013e31816de21e","article-title":"Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men","volume":"48","author":"Dumond","year":"2008","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3851\/IMP1919","article-title":"Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract","volume":"16","author":"Else","year":"2011","journal-title":"Antiviral Therapy"},{"key":"bib26","article-title":"How much do antiretroviral drugs penetrate into the central nervous system?","volume":"4","author":"Ene","year":"2011","journal-title":"Journal of Medicine and Life"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1056\/NEJM199512213332502","article-title":"Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimete","volume":"333","author":"Eron","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"bib28","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.10670","article-title":"More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1","volume":"5","author":"Feder","year":"2016","journal-title":"eLife"},{"key":"bib29","article-title":"HIV drug resistance in drug naive patients","volume-title":"GitHub","author":"Feder","year":"2016","unstructured":"Feder AF, Rhee SY, Holmes SP, Petrov DA, Pennings PS. 2016b. HIV drug resistance in drug naive patients. GitHub. 6aed7af. https:\/\/github.com\/affeder\/HIV-DRM-sweeps\/blob\/master\/dat\/dataset.01.24.txt."},{"key":"bib30","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1534\/g3.119.400605","article-title":"Evolutionary dynamics in structured populations under strong population genetic forces","volume":"9","author":"Feder","year":"2019","journal-title":"G3: Genes, Genomes, Genetics"},{"key":"bib31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1009050","article-title":"The clarifying role of time series data in the population genetics of HIV","volume":"17","author":"Feder","year":"2021","journal-title":"PLOS Genetics"},{"key":"bib32","article-title":"HIV-MDR-evolution","volume-title":"Software Heritage","author":"Feder","year":"2021","unstructured":"Feder AF, Harper K, Brumme CJ, Penning PS. 2021b. HIV-MDR-evolution. Software Heritage. https:\/\/github.com\/federlab\/HIV-MDR-evolution."},{"key":"bib33","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"PNAS"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1097\/QAD.0b013e328311d16f","article-title":"Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen","volume":"22","author":"Fox","year":"2008","journal-title":"AIDS"},{"key":"bib35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004142","article-title":"Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to Cancer therapy","volume":"11","author":"Fu","year":"2015","journal-title":"PLOS Computational Biology"},{"key":"bib36","doi-asserted-by":"publisher","DOI":"10.1088\/1478-3975\/aa7bb3","article-title":"Convection shapes the trade-off between antibiotic efficacy and the selection for resistance in spatial gradients","volume":"14","author":"Gralka","year":"2017","journal-title":"Physical Biology"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the international antiviral Society-USA panel","volume":"68","author":"G\u00fcnthard","year":"2019","journal-title":"Clinical Infectious Diseases"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less","volume":"337","author":"Hammer","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1086\/427192","article-title":"Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy","volume":"191","author":"Harrigan","year":"2005","journal-title":"The Journal of Infectious Diseases"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/2041-210X.12808","article-title":"Soft sweeps and beyond: understanding the patterns and probabilities of selection footprints under rapid adaptation","volume":"8","author":"Hermisson","year":"2017","journal-title":"Methods in Ecology and Evolution"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"10775","DOI":"10.1073\/pnas.1117716109","article-title":"On the rapidity of antibiotic resistance evolution facilitated by a concentration gradient","volume":"109","author":"Hermsen","year":"2012","journal-title":"PNAS"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1086\/648444","article-title":"Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa","volume":"49","author":"Hoffmann","year":"2009","journal-title":"Clinical Infectious Diseases"},{"key":"bib43","first-page":"659","article-title":"Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens","volume":"160","author":"Hogg","year":"1999","journal-title":"CMAJ"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/infdis\/jiq167","article-title":"Differential persistence of transmitted HIV-1 drug resistance mutation classes","volume":"203","author":"Jain","year":"2011","journal-title":"The Journal of Infectious Diseases"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nm.2649","article-title":"A quantitative basis for antiretroviral therapy for HIV-1 infection","volume":"18","author":"Jilek","year":"2012","journal-title":"Nature Medicine"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1086\/380509","article-title":"Incidence of resistance in a double-blind study comparing lopinavir\/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine","volume":"189","author":"Kempf","year":"2004","journal-title":"The Journal of Infectious Diseases"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1073\/pnas.95.20.11514","article-title":"Drug concentration heterogeneity facilitates the evolution of drug resistance","volume":"95","author":"Kepler","year":"1998","journal-title":"PNAS"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-4682-11-41","article-title":"Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs","volume":"11","author":"Koizumi","year":"2014","journal-title":"Theoretical Biology and Medical Modelling"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1126\/science.2467383","article-title":"HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy","volume":"243","author":"Larder","year":"1989","journal-title":"Science"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1126\/science.7542804","article-title":"Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy","volume":"269","author":"Larder","year":"1995","journal-title":"Science"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1126\/science.2479983","article-title":"Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)","volume":"246","author":"Larder","year":"1989","journal-title":"Science"},{"key":"bib52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097482","article-title":"Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up","volume":"9","author":"Lee","year":"2014","journal-title":"PLOS ONE"},{"key":"bib53","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2007.31","article-title":"Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system","volume":"65","author":"Letendre","year":"2008","journal-title":"Archives of Neurology"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","article-title":"Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis","volume":"41","author":"L\u00f3pez-Cort\u00e9s","year":"2002","journal-title":"Clinical Pharmacokinetics"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nature16933","article-title":"Persistent HIV-1 replication maintains the tissue reservoir during therapy","volume":"530","author":"Lorenzo-Redondo","year":"2016","journal-title":"Nature"},{"key":"bib56","doi-asserted-by":"publisher","DOI":"10.1101\/588426","article-title":"The CNS in the face of ART contains T cell origin HIV which can lead to drug resistance","volume-title":"bioRxiv","author":"Lustig","year":"2019"},{"key":"bib57","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7954","article-title":"Comparison of overall and Comorbidity-Free life expectancy between insured adults with and without HIV infection, 2000-2016","volume":"3","author":"Marcus","year":"2020","journal-title":"JAMA Network Open"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"460","DOI":"10.32614\/RJ-2016-059","article-title":"condSURV: an R package for the estimation of the conditional survival function for ordered multivariate failure time data","volume":"8","author":"Meira-Machado","year":"2016","journal-title":"The R Journal"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nm0796-760","article-title":"Ordered accumulation of mutations in HIV protease confers resistance to ritonavir","volume":"2","author":"Molla","year":"1996","journal-title":"Nature Medicine"},{"key":"bib60","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0140-6736(10)60936-1","article-title":"Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in british Columbia, Canada: a population-based study","volume":"376","author":"Montaner","year":"2010","journal-title":"The Lancet"},{"key":"bib61","doi-asserted-by":"publisher","first-page":"E2874","DOI":"10.1073\/pnas.1424184112","article-title":"Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance","volume":"112","author":"Moreno-Gamez","year":"2015","journal-title":"PNAS"},{"key":"bib62","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198504184.001.0001","volume-title":"Virus Dynamics: Mathematical Principles of Immunology and Virology: Mathematical Principles of Immunology and Virology","author":"Nowak","year":"2000"},{"key":"bib63","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1128\/JVI.02154-08","article-title":"In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine","volume":"83","author":"Paredes","year":"2009","journal-title":"Journal of Virology"},{"key":"bib64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002527","article-title":"Standing genetic variation and the evolution of drug resistance in HIV","volume":"8","author":"Pennings","year":"2012","journal-title":"PLOS Computational Biology"},{"key":"bib65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4081\/idr.2013.s1.e5","article-title":"HIV drug resistance: problems and perspectives","volume":"5","author":"Pennings","year":"2013","journal-title":"Infectious Disease Reports"},{"key":"bib66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004000","article-title":"Loss and recovery of genetic diversity in adapting populations of HIV","volume":"10","author":"Pennings","year":"2014","journal-title":"PLOS Genetics"},{"key":"bib67","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/387188a0","article-title":"Decay characteristics of HIV-1-infected compartments during combination therapy","volume":"387","author":"Perelson","year":"1997","journal-title":"Nature"},{"key":"bib68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1137\/S0036144598335107","article-title":"Mathematical analysis of HIV-1 dynamics in vivo","volume":"41","author":"Perelson","year":"1999","journal-title":"SIAM Review"},{"key":"bib69","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/01.aids.0000162337.58557.3d","article-title":"Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice","volume":"19","author":"Phillips","year":"2005","journal-title":"Aids"},{"key":"bib70","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1086\/323088","article-title":"Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine","volume":"184","author":"Picard","year":"2001","journal-title":"The Journal of Infectious Diseases"},{"key":"bib71","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.25.312942","article-title":"Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C","volume-title":"bioRxiv","author":"Posada-C\u00e9spedes","year":"2020"},{"key":"bib72","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nature Medicine"},{"key":"bib73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91219-6","article-title":"Resumption of hiv antigen production during continuous zidovudine treatment","volume":"331","author":"Reiss","year":"1988","journal-title":"The Lancet"},{"key":"bib74","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cmi.2017.06.014","article-title":"Longitudinal trends of HIV drug resistance in a large canadian cohort, 1996-2016","volume":"24","author":"Rocheleau","year":"2018","journal-title":"Clinical Microbiology and Infection"},{"key":"bib75","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s11538-007-9203-3","article-title":"Emergence of HIV-1 drug resistance during antiretroviral treatment","volume":"69","author":"Rong","year":"2007","journal-title":"Bulletin of Mathematical Biology"},{"key":"bib76","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/nm.2892","article-title":"Antiretroviral dynamics determines HIV evolution and predicts therapy outcome","volume":"18","author":"Rosenbloom","year":"2012","journal-title":"Nature Medicine"},{"key":"bib77","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.1073\/pnas.1018360108","article-title":"Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance","volume":"108","author":"Sampah","year":"2011","journal-title":"PNAS"},{"key":"bib78","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/psp4.12200","article-title":"A mathematical model to predict HIV virological failure and elucidate the role of lymph node drug penetration","volume":"6","author":"Sanche","year":"2017","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"bib79","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/infdis\/171.6.1411","article-title":"Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)","volume":"171","author":"Schuurman","year":"1995","journal-title":"Journal of Infectious Diseases"},{"key":"bib80","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/QAD.0b013e328011e691","article-title":"HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance","volume":"21","author":"Shafer","year":"2007","journal-title":"Aids"},{"key":"bib81","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"Shen","year":"2008","journal-title":"Nature Medicine"},{"key":"bib82","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1086\/596736","article-title":"Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes","volume":"199","author":"Simen","year":"2009","journal-title":"Journal of Infectious Diseases"},{"key":"bib83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002773","article-title":"Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization","volume":"16","author":"Strydom","year":"2019","journal-title":"PLOS Medicine"},{"key":"bib84","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/QAD.0b013e3281c61394","article-title":"Stopping antiretroviral therapy","volume":"21","author":"Taylor","year":"2007","journal-title":"AIDS"},{"key":"bib85","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1128\/AAC.04952-14","article-title":"Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs","volume":"59","author":"Thompson","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"bib86","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aap8758","article-title":"Heterogeneous antiretroviral drug distribution and HIV\/SHIV detection in the gut of three species","volume":"11","author":"Thompson","year":"2019","journal-title":"Science Translational Medicine"},{"key":"bib87","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bcp.12403","article-title":"The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future","volume":"79","author":"Tseng","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"key":"bib88","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-019-0133-x","article-title":"The need for mathematical modelling of spatial drug distribution within the brain","volume":"16","author":"Vendel","year":"2019","journal-title":"Fluids and Barriers of the CNS"},{"key":"bib89","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1086\/505147","article-title":"The survival benefits of AIDS treatment in the united states","volume":"194","author":"Walensky","year":"2006","journal-title":"The Journal of Infectious Diseases"},{"key":"bib90","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.4848","article-title":"The global burden of HIV-1 drug resistance in the past 20 years","volume":"6","author":"Zazzi","year":"2018","journal-title":"PeerJ"},{"key":"bib91","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1128\/JVI.78.4.1718-1729.2004","article-title":"Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1","volume":"78","author":"Zhang","year":"2004","journal-title":"Journal of Virology"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/69032\/elife-69032-v1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/69032\/elife-69032-v1.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/69032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T01:39:06Z","timestamp":1699407546000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/69032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":91,"alternative-id":["10.7554\/eLife.69032"],"URL":"https:\/\/doi.org\/10.7554\/elife.69032","archive":["CLOCKSS"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/807560","asserted-by":"subject"},{"id-type":"doi","id":"10.1101\/807560","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.7554\/eLife.69032.sa2","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.69032.sa1","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"assertion":[{"value":"single anonymised","name":"peer_review_transparency","label":"Peer review transparency","group":{"name":"peer_review_taxonomy"}},{"value":"other reviewer(s), editor","name":"peer_review_interaction","label":"Peer review interaction","group":{"name":"peer_review_taxonomy"}},{"value":"review summaries, review reports, author\/editor communication, reviewer identities reviewer opt in, editor identities","name":"peer_review_published","label":"Peer review published","group":{"name":"peer_review_taxonomy"}},{"value":"open (sign in with ORCID iD required)","name":"post_publication_commenting","label":"Post publication commenting","group":{"name":"post_publication_commenting"}}],"article-number":"e69032"}}